Ciptadine

Quick links to important sections

Ciptadine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciptadine

What is Ciptadine? (Cyproheptadine)

Ciptadine is a prescription-only medication whose active ingredient is Cyproheptadine hydrochloride. It is recognized primarily as a first-generation antihistamine that is commonly available in both tablet and oral syrup forms.

Property Description
Active ingredient Cyproheptadine HCl
Form Tablet and oral syrup
Pharmacological class First-generation Antihistamine
Common use Relief of allergic symptoms (e.g., rhinitis, itching, hives)
Key Feature Dual action (Antihistamine & Antiserotonergic)

Ciptadine, which is also widely known under the brand name Periactin, is distinguished by its dual mechanism of action. As a classic antihistamine, it blocks histamine H1 receptors, which are key triggers of allergic responses. Uniquely, it is also a potent antagonist of serotonin receptors. This second action has led to its recognized effect of appetite stimulation, which is a differentiating factor from most newer allergy medications.

The medication has a clinical role in treating various allergy-related symptoms. Its clinical indications include "Perennial and seasonal allergic rhinitis, Vasomotor rhinitis, Allergic conjunctivitis... [and] Mild, uncomplicated allergic skin manifestations." These applications address uncomfortable symptoms affecting the eyes, nose, and skin that are caused by allergies.

Because it is a first-generation antihistamine, Ciptadine is known to have a sedative effect which is a factor users should consider, particularly when compared to non-drowsy alternatives.

Regulatory References

  1. NIH MedlinePlus Drug Information on Cyproheptadine

What side effects are possible with Ciptadine?

Possible Side Effects and Safety Information

The regulatory profile of Ciptadine (Cyproheptadine) emphasizes effects primarily related to the central nervous system and anticholinergic activity. Sedation, drowsiness, and sleepiness are listed as the most frequent and often transient adverse reactions, typically categorized as very common or common in official regulatory documents.

System-Organ Class Groupings

Adverse reactions documented in official labeling extend across multiple body systems, including:

  • Nervous System Disorders: Dizziness, disturbed coordination, confusion, tremor, and, rarely, convulsions.
  • Gastrointestinal Disorders: Common anticholinergic effects such as dry mouth, dry nose/throat, constipation, and epigastric distress.
  • Metabolism and Nutrition Disorders: Increased appetite and subsequent weight gain are officially listed as possible effects.
  • Hepato-biliary Disorders: Rare but serious adverse reactions documented include hepatic failure, hepatitis, and cholestasis.
  • Cardiovascular Disorders: Documented effects include palpitation, tachycardia (rapid heart rate), and hypotension.

Safety Constraints and Considerations

The official prescribing information identifies specific populations and pre-existing conditions where use is restricted or contraindicated. Ciptadine is contraindicated in newborn or premature infants and nursing mothers due to the risk of serious side effects. Geriatric patients (older adults) are noted to be more susceptible to effects such as sedation, dizziness, and hypotension.

Furthermore, the medicine is contraindicated in individuals with specific physiological states, including narrow-angle glaucoma, symptomatic prostatic hypertrophy, pyloroduodenal obstruction, and when concomitantly used with Monoamine Oxidase Inhibitors (MAOIs). These safety constraints frame the use of the medicine according to regulatory standards.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation on Ciptadine (Cyproheptadine) overdose outlines the potential for severe systemic effects and mandates immediate emergency action.

Documented Clinical Signs

Overdose reactions are described as varying across the Central Nervous System (CNS). The presentation may include severe CNS depression, ranging from profound drowsiness and stupor to coma. Conversely, paradoxical CNS stimulation is also documented, which may manifest as restlessness, hallucinations, and acute confusion. Anticholinergic signs, such as fixed or dilated pupils and dry mouth, are documented, alongside cardiovascular effects like tachycardia.

Mandatory Emergency Action

Official guidance states that immediate emergency medical help is required. You must contact emergency services (e.g., 911) immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The regulatory documentation also instructs contacting the Poison Control Center for specialized guidance on managing the overdose.

Severe Outcomes and Supportive Management

The severe consequences listed include convulsions, respiratory arrest, cardiac arrest, and death. The management procedures stipulated include gastric decontamination methods such as gastric lavage and the administration of activated charcoal. Intravenous physostigmine salicylate may be considered by healthcare professionals for treating life-threatening CNS symptoms. Continuous monitoring of vital signs is required, with a specific warning noted regarding the heightened risk of severe outcomes in infants and young children.

Therapeutic Uses of Ciptadine

What Ciptadine Treats: Main Uses and Benefits

Ciptadine is commonly used to help manage symptoms related to inflammatory or irritative states, such as those seen in allergic conditions, and is also considered relevant for certain specific symptom patterns, including some types of recurrent headaches. The medication is generally applied across domains where additional symptomatic support is needed.

Core Therapeutic Uses

Ciptadine is applied in addressing symptom clusters that interfere with daily functioning, which may include manifestations associated with perennial and seasonal allergic rhinitis, allergic conjunctivitis, and various uncomplicated allergic skin conditions like urticaria and widespread pruritus. It is also used in clinical contexts where support for appetite stimulation and weight gain is needed, or for managing recurrent symptom patterns, such as certain vascular headaches. This supportive therapeutic benefit contributes to easing the overall symptom load.

“This medication is considered relevant in clinical contexts that involve addressing both challenging allergic manifestations and poor nutritional intake.”


Quick Fact: Addressing Persistent Itching and Appetite Deficits

A key therapeutic benefit Ciptadine is used for managing is the easing of persistent symptoms related to physical discomfort, such as generalized pruritus (itching) and the systemic imbalance caused by low desire to eat. It contributes to improved day-to-day comfort and assists with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility for Ciptadine (Cyproheptadine) is strictly defined by regulatory documents, which establish specific patient groups who are permitted to use the medicine and those who are formally prohibited.

Age-Group Eligibility Status as per Labeling
Adults Permitted under standard labeled conditions.
Children 2 Years and Older Permitted for approved indications.
Children Under 2 Years Contraindicated (safety and effectiveness not established).
Elderly/Debilitated Patients Contraindicated (due to increased risk of adverse effects).

Absolute Prohibitions

Use is contraindicated and explicitly prohibited in individuals with known hypersensitivity to the drug and in those with specific pre-existing conditions or physiological states, including:

  • Acute asthma attacks
  • Nursing mothers
  • Narrow-angle glaucoma
  • Stenosing peptic ulcer or pyloroduodenal obstruction
  • Symptomatic prostatic hypertrophy or bladder neck obstruction
  • Patients currently receiving Monoamine Oxidase Inhibitor (MAOI) therapy

Restricted or Conditional Use

Use of Ciptadine requires caution in patients with a history of bronchial asthma (outside of an acute attack), hypertension, hyperthyroidism, or increased intraocular pressure. Patients with hepatic or renal impairment may also require restricted use due to the drug's metabolism and excretion profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ciptadine (Cyproheptadine) is characterized by documented pharmacodynamic interactions and strict contraindication rules. These established patterns dictate specific constraints for co-administration.

Interaction Type Interacting Substance/Class Officially Documented Effect
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Co-administration is formally prohibited due to the risk of prolonging and intensifying the anticholinergic effects.
Additive Pharmacodynamic Alcohol, CNS Depressants (e.g., sedatives, tranquilizers) Results in increased additive CNS depression, enhancing effects like sedation and impairment.
Pharmacodynamic Interference Serotonin-Enhancing Antidepressants The anti-serotonin action of Ciptadine may interfere with the effects of these agents, potentially resulting in the recurrence of depression-related symptoms.

The interaction profile also notes that Ciptadine may cause a false positive test result during laboratory drug screening for Tricyclic Antidepressant (TCA) drugs. Furthermore, population-specific constraints emphasize that elderly and debilitated patients are at an increased risk of pronounced interaction-related effects, including heightened sedation, dizziness, and hypotension. The regulatory documents define the product’s interaction structure strictly by these known effects and required prohibitions.

Mechanism of Action

How Ciptadine Works

Ciptadine exerts its action through the competitive antagonism of multiple neuroreceptors. Its primary mechanism involves blocking the Histamine H1 receptor on target cells, preventing the binding of endogenous histamine. This molecular event limits the histamine-induced increase in capillary permeability and the stimulation of peripheral sensory nerves, thereby modulating inflammatory-type signaling.

Simultaneously, Ciptadine acts as an antagonist at several other sites, notably the 5-hydroxytryptamine (Serotonin) 5-HT2 receptors and non-specific Muscarinic Cholinergic receptors. Its central activity, particularly the antiserotonergic action in the hypothalamus, interrupts the normal regulation of the satiety signal, resulting in an altered activity profile of appetite-regulating pathways. The combined antagonism of H1 receptors in the CNS and cholinergic receptors further contributes to the blockade of neurotransmitter action in centers regulating wakefulness and parasympathetic output.

Dosage and Administration Information

Ciptadine is administered via the oral route using a 4 mg tablet or a 2 mg/5 mL oral syrup. The administration protocol is based on standard dosage parameters, with the total amount taken in divided doses two or three times daily. This frequency pattern is structured because the effect of a single dose generally lasts approximately four to six hours.


Standard Administration

For adults, the usual starting dose is 4 mg taken three times daily (TID). The dosage is adjusted based on the individual's response, remaining within a usual daily range of 4 to 20 mg. The maximum recommended daily intake for adults is 32 mg.


Population-Specific Dosing and Procedures

There are distinct dosing rules for specific populations. The maximum daily dose for pediatric patients between 7 and 14 years is 16 mg, and for children aged 2 to 6 years, the limit is 12 mg per day. Doses for children may be calculated based on body weight or surface area. Older adults may be administered doses at the lower end of the range or less frequently due to considerations for reduced drug clearance. When using the liquid form, an accurate measuring device must be employed to ensure precise administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Ciptadine


Evidence for Use in Allergic Conditions

Ciptadine was evaluated in research exploring its application in conditions where symptoms may vary in intensity, such as seasonal and perennial allergies, allergic conjunctivitis, and allergic skin conditions like hives (urticaria). The research base for this use includes historical Randomized Controlled Trials (RCTs) and various comparative studies where the drug was observed in adults and children (typically aged 2 years and older).

These studies mainly focused on outcomes related to physical discomfort, examining how symptoms evolved in the observed populations over short periods. The research landscape is primarily characterized by older trials, as current research often focuses elsewhere. While the existing data indicate patterns related to how symptoms evolved in observed populations, the follow-up durations typically covered only one to four weeks. Therefore, there is limited information for long-term outcomes regarding the sustained relief or maintenance of the drug's effect beyond this short period.

Evidence for Use in Appetite Stimulation and Weight Gain

Research examined Ciptadine's application in cohorts with poor appetite or low weight, where outcomes related to systemic or functional imbalance are a concern. Studies explored this area using more recent research designs, including a number of placebo-controlled Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews.

Findings describe patterns observed in the studies where an association with measured changes in weight metrics was observed in some studies across specific populations, including children with low weight and adults with appetite loss. However, research highlights that follow-up durations were limited, often ranging from 8 weeks to 3 months. Long-term effects are not fully established, and some evidence suggests that the observed patterns were noted to lessen over longer follow-up periods. Data for certain groups, such as the elderly or very young children, remain insufficient to draw conclusions.

What is Still Uncertain About Ciptadine's Evidence Base

A key limitation of the existing research is the reliance on older trial designs, particularly for the core allergic indications. This results in comparative evidence that is limited against newer pharmacological alternatives. The research on headache symptom management also suffers from modest sample sizes and variability. Overall, the evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, and the data for certain complex groups or long-term outcomes remain insufficient.

Key Studies & References

  1. Cyproheptadine: MedlinePlus Drug Information
  2. Safety of Cyproheptadine, an Orexigenic Drug. Analysis of the French National Pharmacovigilance Data-Base and Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Ciptadine (FAQ)


Q: How long does it usually take for Ciptadine to start working for allergy symptoms?

Regulatory information indicates that the effects of the medicine generally begin relatively quickly after administration. The onset of action is often reported to occur within 1 to 2 hours.

Q: What is the typical duration of the effect of one dose of Ciptadine?

According to the official product information, the therapeutic effect from a single dose is described to last approximately four to six hours. This duration is why the administration is typically structured around divided doses taken throughout the day.

Q: Does Ciptadine commonly cause weight gain as a side effect?

Official side effect documentation lists increased appetite and subsequent weight gain among the more common adverse reactions observed in clinical experience. This is a recognized potential effect of the drug.

Q: Why is Ciptadine sometimes associated with an increase in appetite?

The medicine's action profile includes blocking certain serotonin receptors in the brain. This specific action is understood to interrupt the normal regulation of the satiety signal (the sensation of fullness), which can lead to increased appetite.

Q: Is Ciptadine appropriate for use in children?

Ciptadine is contraindicated for use in newborn or premature infants. Official labeling provides specific dosing instructions for children aged 2 years and older, but precise administration protocols and maximum daily limits are defined by the child's age group and weight.

Q: Are there special precautions for older adults who may use Ciptadine?

Official guidance notes that older adults may be more susceptible to certain effects, such as sedation, dizziness, and low blood pressure (hypotension). Regulatory documentation states that dosage should be considered at the lower end of the usual range, or less frequent, for this population.

Q: Is Ciptadine safe to use during pregnancy, according to official sources?

The oral tablet form is designated as US FDA Pregnancy Category B. This classification indicates that while animal studies did not show risk to the fetus, human studies are not fully adequate. Official labeling states that use during pregnancy is considered only if clearly needed and if the potential benefit is determined to outweigh the potential risk.

Q: What does official research evidence say about Ciptadine's effectiveness for its main uses?

The existing research base, including historical studies, indicates its utility for the symptomatic relief of various allergic conditions. These include seasonal allergies, allergic skin conditions (such as hives), and allergic conjunctivitis.

Q: Why is Ciptadine sometimes prescribed for appetite stimulation?

Research has examined its application for appetite stimulation and weight gain in patient cohorts experiencing poor appetite or low weight. This application is connected to the drug’s known effect on the satiety signal.

Q: Can Ciptadine affect a person's ability to drive or operate machinery?

Official warnings describe that due to the potential for effects like drowsiness, sedation, or dizziness, the use of this medicine may impair a person's ability to safely drive a car or operate machinery. Patients are advised to be aware of how the drug affects them.

Q: Are there different forms of Ciptadine, such as tablets, capsules, or liquid?

According to official regulatory documents, the drug is available in two primary dosage forms: an oral tablet and an oral solution (liquid/syrup) to be taken by mouth.

Q: Is Ciptadine commonly prescribed for skin conditions like hives or itching?

Yes, official regulatory indications include its use to relieve the itching associated with allergic skin conditions and to treat various forms of hives (urticaria).

Q: Is Ciptadine an over-the-counter medicine or is it prescription-only?

In the United States, Ciptadine (Cyproheptadine) is classified as a prescription-only (Rx) medicine, meaning it requires an authorized prescription for dispensing.

Q: What should I do if I miss a scheduled dose of Ciptadine?

Official regulatory information includes general guidance regarding missed doses. This guidance typically describes a protocol where the missed dose is skipped if the next dose is due soon, and states that doubling a dose is not advised.

Q: Can Ciptadine be used to help with certain types of headaches, like migraines?

Research has examined its application for the prophylaxis (prevention) of migraine headaches. This use is sometimes referenced in medical monographs, although it may be considered off-label in some regulatory documents.

Q: Can Ciptadine affect the results of an allergy skin test?

Yes, official documentation states that the medicine may suppress the wheal and flare reactions associated with antigen skin testing (allergy tests). For this reason, administration is often discontinued before testing.

Q: Is Ciptadine considered to be a controlled substance?

The drug is not officially designated as a federally controlled substance under the U.S. Controlled Substances Act.

Q: Does Ciptadine interact with any common herbal supplements?

The official patient guidance describes the importance of informing a healthcare provider of all medications, including natural products and herbal supplements, as this allows for the review of potential interactions.

Q: Are there different brand names for the drug Ciptadine?

The drug is known by its generic name, Ciptadine (Cyproheptadine), and has been marketed under brand names such as Periactin.

Q: What research has been done on Ciptadine's use for sexual dysfunction?

Research has examined its use in the management of drug-induced sexual dysfunction. This application is sometimes categorized as off-label and may be referenced in medical monographs.

Q: What are the signs of taking too much Ciptadine (overdosage symptoms)?

Signs of overdosage involve effects on the central nervous system, and can include dilated pupils, agitation, hallucinations, fever, rapid heartbeat, and convulsions. Official information describes that if an overdose is suspected, contacting emergency medical services or a poison control center is the appropriate recommended procedure.

Q: Can Ciptadine be taken with or without food?

According to patient instructions, the medicine may be taken with or without food. Official patient instructions indicate that taking the medicine with food is an option that may be considered if an upset stomach occurs.

Q: Does Ciptadine need to be taken at the exact same time every day?

Standard patient instructions state that taking the medicine at around the same time(s) every day may help to maintain a consistent level of the medicine in the body.

Q: What is the official information regarding Ciptadine and vision problems?

Official documentation lists several vision-related side effects, including blurred vision, double vision (diplopia), and, rarely, reports of other more serious vision problems. Use is also contraindicated in patients with narrow-angle glaucoma.

Q: Does Ciptadine contain any common allergens, such as lactose or gluten?

The full official labeling for the drug product contains a list of inactive ingredients (excipients). For individuals with specific allergies, such as to lactose or gluten, this list provides the necessary details to confirm ingredients.

How should Ciptadine be stored and disposed of?

How to Store and Dispose of Ciptadine

Ciptadine (Cyproheptadine Hydrochloride) must be stored according to specific regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Requirement Official Condition
Temperature Controlled Room Temperature (20 C to 25 C, with excursions allowed to 30 C)
Environment Protect from moisture and excess heat.
Handling Do not freeze the medicine.
Container Keep in the original, tightly closed container.

Child Safety and Disposal

Ciptadine must be stored out of the sight and reach of children. Regarding disposal, the product is not on the FDA flush list and should not be discarded down the toilet. Unused or expired medication must be disposed of through a drug take-back program or by following the specific household disposal procedure defined by authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciptadine found in:

A-Z Index: